Lv4
490 积分 2025-02-28 加入
Innovative Anti‐CD38 and Anti‐BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
3个月前
已完结
Outcomes and Prognostic Indicators in Daratumumab‐Refractory Multiple Myeloma: A Multi center Real‐World Study of Elotuzumab, Pomalidomide, and Dexa methasone in 247 Patients
3个月前
已完结
Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real World Experience with 321 Cases outside of Controlled Clinical Tri als
3个月前
已完结
Phase II Trial of Elo tuzumab With Pomalidomide and Dexamethasone for Daratumumab Refractory Multiple Myeloma
3个月前
已完结
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
3个月前
已完结
Antibody-Drug Conjugates, Bispecific Antibodies and CAR-T Cells Therapy in Multiple Myeloma
3个月前
已完结
Outcomes of Pa tients With Multiple Myeloma Refractory to CD38‐Targeted Monoclonal Antibody Therapy
3个月前
已完结
Teclistamab in patients with multiple myeloma and impaired renal function
4个月前
已完结
皖公网安备34019202002308
